Pharmaceutical Cleaning Validation Guidance: A Global Regulatory Perspective

/ Pharma Articles / By

Pharmaceutical Cleaning Validation Guidance: A Global Regulatory Perspective

I. Executive Summary

The pharmaceutical industry operates under stringent regulatory frameworks worldwide to ensure the safety, efficacy, and quality of medicinal products. A critical aspect of these frameworks is the validation of cleaning processes used in manufacturing facilities. This article provides a comprehensive overview of the latest cleaning validation guidance issued by key global regulatory agencies, including the United States Food and Drug Administration (US FDA), the Medicines and Healthcare products Regulatory Agency (MHRA), the European Union Good Manufacturing Practice (EU GMP), Health Canada, the Pharmaceutical Inspection Co-operation Scheme (PIC/S), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the World Health Organization (WHO), and India’s Schedule M. The analysis highlights a consistent global trend towards risk-based approaches and the implementation of Health-Based Exposure Limits (HBELs) to establish scientifically justified acceptance criteria. By summarizing the specific requirements of each authority and presenting a comparative analysis, this report aims to provide regulatory affairs professionals with a clear understanding of the current global landscape of cleaning validation regulations, thereby facilitating compliance and ensuring the prevention of cross-contamination in pharmaceutical manufacturing.

II. Introduction to Pharmaceutical Cleaning Validation

In the pharmaceutical industry, cleaning validation plays an indispensable role in safeguarding the integrity of drug products.1 The primary objective is to prevent cross-contamination, which can compromise the safety, efficacy, and overall quality of manufactured medicines.1 Regulatory bodies worldwide mandate adherence to Good Manufacturing Practices (GMP), and cleaning validation stands as a cornerstone of these practices.1 It ensures that manufacturing equipment is consistently cleaned to prevent the carryover of residues from previous products or cleaning agents to subsequent batches.1

Cleaning validation can be defined as the process of establishing documented evidence that a cleaning procedure effectively removes residues, such as active pharmaceutical ingredients, excipients, and cleaning agents, to predetermined acceptable levels.3 The overarching goals are to prevent unacceptable contamination of future products and to ensure patient safety.1 Over time, the requirements and expectations surrounding cleaning validation have become increasingly complex, reflecting a heightened regulatory scrutiny on pharmaceutical manufacturing processes.6 This report delves into the latest guidance from various regulatory agencies to provide a comprehensive understanding of the current standards.

III. Cleaning Validation Guidance by Regulatory Agency

  • A. United States Food and Drug Administration (US FDA)
  • The foundational regulatory requirement for cleaning in the United States is outlined in Title 21 of the Code of Federal Regulations (CFR), specifically Part 211.67.3 This regulation dictates that all equipment and utensils used in the manufacturing of pharmaceutical products must be cleaned, maintained, and, where necessary, sanitized or sterilized at appropriate intervals to prevent malfunctions or contamination that could alter the safety, identity, strength, quality, or purity of the drug product.3
  • While the FDA has not released a specific guidance document dedicated solely to cleaning validation for pharmaceutical firms in recent years, the “Guide to Inspections: Validation of Cleaning Processes,” issued in July 1993, remains a crucial reference for both manufacturers and FDA investigators.7 This guide discusses practices that have been deemed acceptable or unacceptable and emphasizes that various approaches can be valid for cleaning validation.8 It establishes the FDA’s expectation for written general procedures detailing how cleaning processes will be validated, including the assignment of responsibility, the definition of acceptance criteria, and the circumstances requiring revalidation.8 Furthermore, the guide specifies that firms should prepare specific written validation protocols in advance for each manufacturing system or piece of equipment, addressing aspects such as sampling procedures and the analytical methods to be employed, including their sensitivity.8 The FDA underscores that the rationale behind the established residue limits should be scientifically justifiable, practical, achievable, and verifiable, based on the manufacturer’s understanding of the materials involved.8 Notably, due to the wide array of equipment and products in the pharmaceutical industry, the FDA does not intend to prescribe specific acceptance specifications or analytical methods for cleaning validation.8
  • The FDA places a significant emphasis on the evaluation of worst-case scenarios in cleaning validation programs.9 As highlighted in a recent GMP news article referencing an FDA Warning Letter, the agency is particularly interested in improvements to cleaning validation programs that thoroughly address the most challenging conditions in drug manufacturing.9 This includes identifying and assessing worst-case scenarios for drugs exhibiting higher toxicities, greater drug potencies, lower solubility in cleaning solvents, and inherent characteristics that make them difficult to clean.9 The FDA also expects manufacturers to determine appropriate swabbing locations, focusing on areas that are most difficult to clean, and to establish maximum hold times for equipment before cleaning is initiated.9
  • The FDA expects manufacturers to employ appropriate sampling procedures to assess the effectiveness of their cleaning processes.1 Although not explicitly mandated in regulations, the pharmaceutical industry commonly utilizes both direct surface sampling, often referred to as the swab method, and indirect sampling, such as rinse sampling.1 Analytical methods used for detecting residues should be validated to ensure their reliability and should possess sufficient sensitivity to detect contaminants at the established acceptance levels.10 Total Organic Carbon (TOC) analysis is recognized by the FDA as an acceptable method for routinely monitoring residues and for cleaning validation, provided it is established that the substances being removed are organic and contain carbon that can be oxidized under the test conditions.7
  • During FDA inspections, cleaning validation studies are subject to extensive review and assessment.11 Common deficiencies that lead to FDA 483 observations include the development of inadequate cleaning validation protocols, often lacking clearly defined acceptance criteria, and the execution of insufficient validation studies that fail to account for process variability or the full range of products and equipment used.12 Another frequent cause for concern is the failure to establish and scientifically justify residue limits, potentially leading to unsafe levels of contamination.12 Furthermore, inadequate or inconsistent monitoring of cleaning procedures, including the absence of periodic revalidation, is a common issue identified during inspections.12
  • Insight 1: The FDA’s approach to cleaning validation is characterized by a principles-based framework that provides flexibility to manufacturers in designing and implementing their programs. While the 1993 inspection guide remains a key reference, the agency’s current focus during inspections, particularly on worst-case scenarios and the avoidance of common deficiencies, underscores the need for robust, scientifically sound, and thoroughly documented cleaning validation programs.
  • Insight 2: The FDA emphasizes the importance of a comprehensive understanding of the manufacturing process and potential contamination risks as a foundation for an effective cleaning validation program. This understanding should be derived from a thorough risk assessment that identifies potential sources of contamination and guides the development of appropriate cleaning procedures and validation strategies.3
  • Table Suggestion:
Key Expectation of US FDAReference
Comply with 21 CFR Part 211.673
Refer to “Guide to Inspections: Validation of Cleaning Processes”7
Address worst-case scenarios9
Utilize appropriate sampling methods (swab and/or rinse)1
Employ validated analytical methods (e.g., TOC)7
Establish scientifically justifiable residue limits8
Conduct thorough and comprehensive validation studies12
Implement ongoing monitoring and periodic revalidation6
Perform risk assessment to identify contamination sources3
  • B. Medicines and Healthcare products Regulatory Agency (MHRA)
  • The MHRA, the regulatory authority in the United Kingdom, aligns its expectations for cleaning validation with the principles outlined in EU GMP Volume 4, Annex 15, but also provides its own interpretations and emphasizes specific areas based on findings from inspections.13
  • A critical aspect highlighted by the MHRA is the importance of utilizing Health-Based Exposure Limits (HBELs), such as Permitted Daily Exposure (PDE) values, in both cleaning validation and the control of cross-contamination.13 The agency has clarified that companies are responsible for establishing and adhering to relevant HBEL values.13
  • MHRA’s GMP inspectors have frequently noted a lack of scientific rigor in some cleaning validation programs. A common criticism is the failure to adequately integrate all product contact parts and crucial cleaning processes, particularly manual cleaning, into the validation studies.13
  • The MHRA advocates for a robust risk-based approach to cleaning validation.6 This approach necessitates that validation studies thoroughly evaluate factors such as the design and cleanability of equipment, the compatibility of cleaning agents with the residues and equipment materials, the frequency of routine cleaning cycles, and the potential for cross-contamination between different products.6
  • The agency shows a preference for the adoption of digital record-keeping systems for managing cleaning validation data. Electronic logs, real-time status dashboards, and secure, audit-ready data trails are viewed favorably, while handwritten logs or disconnected systems may raise concerns during inspections.6
  • The MHRA emphasizes the significance of providing role-specific training to personnel involved in manual cleaning, sampling procedures, and visual inspections. They have observed that audit failures often result from inconsistencies in the execution of cleaning procedures rather than inadequacies in the Standard Operating Procedures (SOPs) themselves.6
  • Current guidance from the MHRA underscores the need for enhanced risk management through the integration of digital tools and the adoption of modern analytical methods to proactively detect cleaning failures before they escalate into significant compliance issues.14
  • Guidance specifically for manufacturers of ‘specials’ (unlicensed medicines) identifies cleaning validation as a significant change that requires implementation.15
  • The MHRA places a strong focus on controlling cross-contamination in facilities and equipment that are shared for the production of multiple products. They emphasize the necessity of using HBEL values that are of the appropriate magnitude, determined by individuals with extensive knowledge and experience in toxicology, to establish effective cross-contamination control strategies.16 Risk assessments conducted to support these strategies should explicitly reference the relevant HBEL levels.16 The agency has also clarified that sole reliance on visual inspection to confirm cleanliness after cleaning validation may not be acceptable in all circumstances, particularly if the residue limits required to meet the HBEL cannot be consistently and readily seen at the visual threshold of the product contaminant.16 In such cases, analytical testing at product changeover is generally expected to provide a more discerning measure of cleaning success.17
  • Insight 3: The MHRA’s regulatory approach to cleaning validation is characterized by a strong emphasis on scientific justification, particularly the application of HBELs in risk assessment and cross-contamination control. The agency also actively encourages the adoption of digital technologies to enhance the reliability and auditability of cleaning validation processes.
  • Insight 4: The MHRA’s specific concerns regarding the integration of manual cleaning into validation studies highlight the need for manufacturers to develop robust validation strategies that adequately address the variability associated with manual cleaning procedures. This includes ensuring thorough training, clear and detailed SOPs, and potentially more frequent monitoring or verification of manually cleaned equipment.
  • Table Suggestion:
Key Expectation of MHRAReference
Align with EU GMP Annex 1513
Utilize Health-Based Exposure Limits (HBELs)13
Employ a risk-based approach6
Prefer digital record-keeping systems6
Ensure role-specific training for cleaning personnel6
Thoroughly validate manual cleaning processes13
Justify reliance on visual inspection based on HBELs16
Conduct risk assessments referencing HBEL levels16
  • C. European Union Good Manufacturing Practice (EU GMP)
  • Annex 15 of the EU GMP Guide to Good Manufacturing Practice, which became operational on October 1, 2015 18, provides a comprehensive framework for qualification and validation, including a dedicated section on cleaning validation.6 This framework places a strong emphasis on patient safety through the application of scientifically derived Health-Based Exposure Limits (HBELs).6
  • According to Annex 15, residue limits for cleaning validation must be established based on toxicological data, such as the Permitted Daily Exposure (PDE) and the Maximum Allowable Carryover (MAC), considering the most challenging product scenarios that may occur when using shared equipment.6
  • The EMA encourages manufacturers to integrate both historical dosage data and modern statistical tools to establish well-justified cleaning thresholds. This approach signifies a move beyond reliance on visual inspection alone and the use of arbitrary limits.6
  • Annex 15 mandates a lifecycle management approach for cleaning validation, which includes the periodic reassessment of residue limits, particularly in response to changes in product formulation, the introduction of new equipment, or revisions to HBELs based on updated toxicological data.6
  • The revised Annex 1 of the EU GMP Guide, concerning the Manufacture of Sterile Medicinal Products, published in August 2022 with most requirements becoming effective on August 25, 2023 21, introduces significant changes impacting cleaning and disinfection practices in sterile manufacturing environments.
  • The revised Annex 1 places a greater emphasis on the validation of disinfection processes, specifying that manufacturers must demonstrate the suitability and effectiveness of disinfectants in the specific manner in which they are used and on the particular types of surface materials encountered in their facilities.21 Standard suspension testing of disinfectants is no longer considered sufficient to meet these requirements.21
  • The guidelines also clearly state that cleaning programs must be effective in removing any residues left by the disinfectants themselves.22
  • Furthermore, Annex 1 specifies that disinfectants and detergents used in Grade A and Grade B areas of sterile manufacturing facilities must be sterile prior to their use.21
  • The European Medicines Agency (EMA) provides additional interpretations of the EU GMP guidelines through various Questions and Answers (Q&As) documents, offering further clarity on specific aspects of GMP compliance, including cleaning validation.25
  • The Active Pharmaceutical Ingredients Committee (APIC), a sector group of the European Chemical Industry Council (CEFIC), has published a widely recognized “Guidance on Aspects of Cleaning Validation in Active Pharmaceutical Ingredient Plants.” The latest version of this guidance was finalized in February 2021.26
  • This APIC guidance provides practical advice on various aspects of cleaning validation in API manufacturing, including methods for calculating acceptance criteria using both health-based data, such as Acceptable Daily Exposure (ADE) and Permitted Daily Exposure (PDE), and general limits.27
  • It also addresses different levels of cleaning that may be appropriate, the control of the cleaning process to ensure its consistency, the use of bracketing and worst-case rating to streamline validation efforts, and the determination of the amount of residue remaining after cleaning.27
  • Insight 5: The EU GMP guidelines, particularly Annex 15, establish a robust and science-driven framework for cleaning validation, with a strong emphasis on the use of HBELs to ensure patient safety. The recent revisions to Annex 1 for sterile products further highlight the importance of effective cleaning and disinfection in these critical manufacturing environments.
  • Insight 6: The EMA’s encouragement of a data-driven approach to setting cleaning limits, combined with the specific guidance provided by APIC for API manufacturers, indicates a clear expectation for manufacturers to move beyond traditional, less scientifically grounded methods of determining acceptable residue levels. This shift aims to enhance the overall rigor and reliability of cleaning validation programs across the European Union.
  • Table Suggestion:
Key Requirement of EU GMPReference
Comply with Annex 15 of the EU GMP Guide6
Utilize Health-Based Exposure Limits (HBELs)6
Integrate statistical and historical data for setting limits6
Follow a lifecycle management approach6
Comply with revised Annex 1 for sterile products21
Refer to EMA Q&As for interpretation25
Consider APIC guidance for API manufacturing26
  • D. Health Canada
  • Health Canada’s “Cleaning Validation Guidelines (GUI-0028),” published on June 29, 2021 4, provide detailed guidance for validating cleaning procedures in the manufacturing of pharmaceuticals, biological drugs, and radiopharmaceuticals sold in Canada.4 This guideline supersedes the previous version issued on January 1, 2008.30
  • The guidelines address the validation of equipment cleaning for the removal of residues from previous production runs, including active ingredients, by-products, intermediates, cleaning agents, and processing agents, as well as the control of potential microbial contaminants.4
  • Health Canada emphasizes the application of Quality Risk Management (QRM) principles throughout the cleaning validation process to control cross-contamination risks.4
  • The guidelines advocate for a comprehensive Cleaning Validation Master Plan and a lifecycle approach that includes three phases: cleaning process design and development, cleaning process qualification, and ongoing monitoring.4
  • Health Canada provides examples of factors to consider when assessing worst-case products for cleaning validation, including the HBEL of the residue, the difficulty in cleaning, the solubility of residues, and the physical characteristics of the product.4
  • The guidelines offer detailed instructions for ensuring the consistency of manual cleaning procedures, including having adequately detailed instructions, establishing operator training programs, and ensuring proper documentation.4
  • Health Canada highlights the importance of visual inspections, equipment sampling using methods like swabbing and rinsing, and establishing cleaning limits based on toxicological evaluation, including HBELs.4 It is Health Canada’s intention to align with the guidance adopted by PIC/S on the use of toxicological evaluation in setting these limits.4
  • The guidelines stress the need for ongoing monitoring of cleaning effectiveness, a robust change control system to manage any changes that could impact cleaning validation, and re-qualification of cleaning processes as necessary.4
  • Insight 7: Health Canada’s 2021 Cleaning Validation Guidelines represent a comprehensive and up-to-date approach that aligns closely with international standards, particularly those of PIC/S, especially in the critical area of utilizing HBELs for setting cleaning limits. This alignment underscores Canada’s commitment to global harmonization in pharmaceutical manufacturing regulations.
  • Insight 8: The detailed guidance provided by Health Canada on various aspects of cleaning validation, including the lifecycle approach and specific considerations for manual cleaning processes, indicates a thorough understanding of the complexities involved in ensuring effective and consistent cleaning in pharmaceutical manufacturing facilities.
  • Table Suggestion:
Key Requirement of Health CanadaReference
Comply with Cleaning Validation Guidelines (GUI-0028)4
Apply Quality Risk Management (QRM) principles4
Follow a Cleaning Validation Master Plan and lifecycle approach4
Assess worst-case products using HBELs and other factors4
Ensure consistency in manual cleaning procedures4
Establish limits based on toxicological evaluation (HBELs)4
Align with PIC/S guidance on HBELs4
Implement ongoing monitoring, change control, and revalidation4
  • E. Pharmaceutical Inspection Co-operation Scheme (PIC/S)
  • The Pharmaceutical Inspection Co-operation Scheme (PIC/S) is instrumental in promoting the harmonization of Good Manufacturing Practice (GMP) standards among its participating authorities worldwide.2
  • Annex 15 of the PIC/S GMP Guide (PE 009-15), with the latest version effective from March 1, 2015 33, provides comprehensive guidance on qualification and validation, including specific requirements for cleaning validation (Section 10).38
  • Annex 15 emphasizes that cleaning validation should encompass all product contact surfaces and also consider the potential risks associated with microbial and endotoxin contamination.33
  • The guideline highlights the importance of taking into account the duration between the completion of manufacturing and the commencement of cleaning, as well as the time elapsed between cleaning and the subsequent use of the equipment (dirty and clean hold times).33
  • PIC/S recommends employing a worst-case product approach for cleaning validation, supported by a sound scientific rationale for the selection of the worst-case product, and assessing the potential impact of introducing new products to the manufacturing site.33 Criteria for determining the worst-case product may include factors such as solubility, cleanability, toxicity, and potency.33
  • Cleaning validation protocols should clearly specify the locations to be sampled, the rationale for selecting these locations, and the defined acceptance criteria for residues.33
  • Sampling procedures should include both swabbing and/or rinsing techniques, as appropriate for detecting both insoluble and soluble residues, and it must be demonstrated that the chosen sampling methods allow for adequate recovery of residues from all product contact materials using the selected sampling methods.33
  • The cleaning procedure should be performed an appropriate number of times, based on a thorough risk assessment, to provide sufficient evidence that the cleaning method is validated and consistently meets the established acceptance criteria.33
  • In cases where manual cleaning of equipment is performed, PIC/S stresses the particular importance of confirming the effectiveness of the manual cleaning process at a justified frequency.33
  • The PIC/S Guideline on Exposure Limits (PI 046-1), which became effective on July 1, 2018 2, aligns with the risk-based approach advocated by the EMA and provides detailed guidance on setting health-based exposure limits for use in risk identification during the manufacture of different medicinal products in shared facilities.4
  • PIC/S also issues Aide-Mémoires, such as PI-052-1, which offer recommendations for inspectors on how to assess Health Based Exposure Limit (HBEL) assessments and their application in Quality Risk Management systems.6
  • Insight 9: PIC/S plays a pivotal role in fostering the convergence of global GMP standards, with Annex 15 serving as a widely recognized and adopted guideline for cleaning validation. The emphasis on risk management and the use of HBELs reflects a commitment to contemporary best practices in pharmaceutical manufacturing.
  • Insight 10: The PIC/S guidelines clearly state that retrospective validation is no longer considered an acceptable approach for demonstrating the effectiveness of cleaning procedures.33 This reinforces the expectation for manufacturers to conduct prospective validation studies to ensure that their cleaning processes are effective and reliable before being implemented in routine production.
  • Table Suggestion:
Key Recommendation of PIC/SReference
Comply with Annex 15 of the PIC/S GMP Guide33
Utilize Health-Based Exposure Limits (HBELs)4
Employ a risk-based approach33
Consider dirty and clean hold times33
Adopt a worst-case product approach with scientific rationale33
Specify sampling locations, rationale, and acceptance criteria33
Demonstrate recovery for sampling methods33
Confirm effectiveness of manual cleaning frequently33
No retrospective validation33
  • F. Japan (Pharmaceuticals and Medical Devices Agency – PMDA)
  • The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan is responsible for enforcing the GMP regulations established by the Ministry of Health, Labour and Welfare (MHLW).43 Japan’s GMP standards are designed to align with international norms to facilitate global trade and ensure product quality.45 Japan has also been a participating authority in PIC/S since July 2014.48
  • The Japanese GMP Ministerial Ordinance emphasizes the need for scientific verification and thorough documentation of both manufacturing methods and quality control procedures.48
  • Pharmaceutical facilities and equipment in Japan must adhere to specific standards that include cleaning validation and disinfection practices, which must follow defined protocols to prevent microbial contamination.44 The design of facilities should facilitate these practices, featuring surfaces that are easy to clean and can withstand commonly used disinfectants.44
  • The PMDA conducts comprehensive GMP inspections of both domestic and international manufacturing sites, including pre-approval inspections for new drugs and periodic inspections (typically every five years) to ensure ongoing compliance with GMP requirements.43 As part of these inspections, manufacturers are usually required to submit reports detailing their cleaning validation studies.50
  • To provide specific guidance on manufacturing and quality control, the MHLW has prepared a “GMP Guideline for Drug Products”.51
  • The PMDA also refers to the ICH Q7 guideline on Good Manufacturing Practice for Active Pharmaceutical Ingredients, which includes a dedicated section (Section 12.7) on cleaning validation.48 This section recommends that cleaning procedures should typically be validated, especially in situations or process steps where contamination or carryover of materials poses the greatest risk to API quality.52 It suggests that if various APIs or intermediates are manufactured using the same equipment and cleaning process, a representative intermediate or API can be selected for cleaning validation. This selection should be based on factors such as solubility, the difficulty of cleaning, and the calculation of residue limits based on potency, toxicity, and stability.52 The cleaning validation protocol should describe the equipment to be cleaned, the procedures, the materials used, the acceptable cleaning levels, the parameters to be monitored and controlled, and the analytical methods employed, including the type of samples to be obtained and how they are collected and labeled.52
  • Insight 11: As a participant in PIC/S and through its alignment with ICH guidelines, the PMDA in Japan adheres to internationally recognized standards for GMP, including a clear expectation for robust cleaning validation programs within pharmaceutical manufacturing operations. This commitment ensures that drug products marketed in Japan meet high standards of quality and safety.
  • Insight 12: The PMDA’s specific adoption of ICH Q7 for API manufacturing guidelines indicates that the principles of cleaning validation for active pharmaceutical ingredients in Japan are consistent with global best practices. This includes the emphasis on a science-based approach to selecting representative compounds for validation and establishing acceptable residue limits.
  • Table Suggestion:
Key GMP Requirement in Japan (PMDA)Reference
Comply with MHLW Ministerial Ordinance No. 179 (GMP)44
Align with ICH Quality Guidelines48
Implement cleaning validation and disinfection protocols44
Maintain thorough documentation and records44
Undergo GMP inspections by PMDA43
Refer to ICH Q7 for API cleaning validation48
  • G. World Health Organization (WHO)
  • The World Health Organization (WHO) plays a critical role in providing guidelines that serve as a basis for the harmonization of pharmaceutical quality assurance practices on a global scale.2
  • WHO Technical Report Series (TRS) No. 1033, Annex 2, published in 2021, offers comprehensive “Points to consider when including Health-Based Exposure Limits (HBELs) in cleaning validation”.54 This annex strongly advocates for a risk and science-based approach to cleaning validation, with the central element being the use of HBELs derived from thorough pharmacological and toxicological evaluations.55
  • Annex 2 of TRS 1033 covers a wide range of critical aspects of cleaning validation, including the necessary documentation, considerations for equipment, the selection and use of cleaning agents, appropriate sampling techniques (swab, rinse, visual inspection), the importance of cleanability studies, the implementation of robust risk management strategies, the process of setting HBELs, the establishment of scientifically justified acceptance criteria (such as Maximum Safe Carryover (MSC) and Maximum Safe Surface Residue (MSSR) values), the selection and validation of analytical procedures, the maintenance of data integrity, the distinction between cleaning validation and cleaning verification, the role of visual cleanliness, the assessment of cleaning process capability, the training of personnel, and the integration of cleaning validation within a product’s lifecycle management.55
  • WHO guidelines support the use of a worst-case product approach for selecting representative Active Pharmaceutical Ingredients (APIs) to validate cleaning procedures. This approach involves considering factors such as the solubility and the difficulty of cleaning the API, as well as calculating residue limits based on its potency, toxicity, and stability.2
  • The WHO emphasizes the importance of continuous monitoring of cleaning effectiveness through both analytical testing and thorough visual examinations.2
  • Furthermore, the WHO’s guidelines on validation, as detailed in TRS 1019, Annex 3, define cleaning validation as the provision of documented evidence that cleaning procedures effectively remove residues to predetermined acceptable levels, taking into account crucial factors such as batch size, dosing, toxicology, and the size of the equipment used in manufacturing.5
  • Insight 13: The WHO’s guidelines, particularly TRS 1033 Annex 2, represent a significant effort to establish globally harmonized standards for cleaning validation. The strong emphasis on the use of Health-Based Exposure Limits and a comprehensive risk management framework reflects the current scientific consensus on best practices in pharmaceutical manufacturing.
  • Insight 14: The WHO’s comprehensive approach to cleaning validation, which encompasses all stages from the initial design of cleaning procedures to their ongoing verification and management throughout the product lifecycle, underscores the importance of integrating cleaning validation as a fundamental component of the overall pharmaceutical quality system.
  • Table Suggestion:
Key Recommendation of WHOReference
Refer to TRS 1033 Annex 2 for HBELs in cleaning validation54
Adopt a risk and science-based approach55
Utilize Health-Based Exposure Limits (HBELs)55
Support the worst-case product approach2
Emphasize continuous monitoring2
Define cleaning validation in TRS 1019 Annex 35
Cover documentation, equipment, sampling, and other aspects55
  • H. Schedule M (India)
  • Schedule M of the Drugs and Cosmetics Rules, 1945, outlines the Good Manufacturing Practices (GMP) that pharmaceutical manufacturers in India must adhere to.6 The revised Schedule M, notified on December 28, 2023, aims to bring Indian pharmaceutical regulations in line with global standards, particularly those recommended by the WHO.61
  • The revised Schedule M places a strong emphasis on the qualification and validation of equipment used in pharmaceutical manufacturing as a crucial aspect of demonstrating GMP compliance.61 Proper documentation of these activities is also a key requirement.61
  • It mandates the implementation of a Pharmaceutical Quality System (PQS) and emphasizes the principles of Quality Risk Management (QRM) throughout the manufacturing and quality control processes.61
  • Sanitation and hygiene practices are given significant attention in the revised guidelines to prevent contamination at all stages of the manufacturing process.64
  • The revised Schedule M explicitly requires cleaning validation to confirm the effectiveness of cleaning procedures in removing a wide range of potential contaminants, including biological substances, growth media, process reagents, cleaning agents, and inactivation agents. It also stresses the importance of careful consideration for cleaning validation when campaign-based production is practiced.70
  • To facilitate the adoption of these enhanced standards, the implementation deadline for the revised Schedule M has been extended until December 31, 2025, for small and medium-sized pharmaceutical manufacturing units with an annual turnover of less than INR 2.5 billion.62
  • Insight 15: The revised Schedule M in India marks a significant step towards aligning the country’s pharmaceutical manufacturing standards with global benchmarks, particularly those set by the WHO. This move is expected to enhance the international acceptance and competitiveness of Indian pharmaceutical products.
  • Insight 16: The specific inclusion of cleaning validation requirements within the revised Schedule M, especially the emphasis on biological substances and campaign manufacturing, reflects a growing regulatory focus in India on preventing cross-contamination in diverse pharmaceutical production environments.
  • Table Suggestion:
Key Requirement of Revised Schedule M (India)Reference
Align with global standards (WHO-GMP)61
Emphasize qualification and validation of equipment61
Implement Pharmaceutical Quality System (PQS)61
Emphasize Quality Risk Management (QRM)61
Focus on sanitation and hygiene64
Require cleaning validation, especially for biologicals70
Extend implementation deadline for SMEs until Dec 202562

IV. Comparative Analysis of Cleaning Validation Requirements

Regulatory AgencyUS FDAMHRAEU GMPHealth CanadaPIC/SPMDA JapanWHOSchedule M India
Emphasis on HBELsYes (implicit)Yes (PDE)Yes (PDE, MAC)Yes (HBEL)Yes (PDE, ADE)Yes (via ICH Q7)Yes (HBEL)Yes (aligning)
Risk-Based ApproachYesYesYesYesYesYesYesYes
Validation Protocol RequirementsGeneral procedures, specific protocolsDetailed protocols requiredComprehensive protocols requiredDetailed protocols requiredDetailed protocols requiredShould describe equipment, procedures, analytical methodsShould be described in master planRequired
Sampling MethodsSwab, RinseSwab, RinseSwab, RinseSwab, Rinse, PlaceboSwab, RinseSwab, RinseSwab, Rinse, VisualNot specified
Acceptance Criteria (Examples)Scientifically justifiable, practical, achievable, verifiableBased on HBELsBased on HBELs, visual cleanBased on HBELs, visual cleanBased on HBELs, visual cleanPractical, achievable, verifiable (via ICH Q7)Based on HBELs (MSC, MSSR)Not specified
Number of Validation BatchesRisk-basedRisk-basedRisk-based (at least 3)Predetermined numberRisk-based (at least 3)Not specifiedNot specifiedNot specified
Cleaning Agent RequirementsEasily removable, known compositionCompatibility, residue removalEffective removal, sterile for Grades A/BKnown composition, easily removableEfficiency of removalNot specifiedEffective removalNot specified
Revalidation ExpectationsWhen changes occur, as neededAfter changes, periodicallyAfter changes, periodicallyAfter changes, periodicallyAfter changes, periodicallyAfter changes, periodicallyAfter changes, periodicallyAfter changes, periodically
Documentation and Record-KeepingWritten procedures, validation reportsDigital logs, validation reportsDetailed protocols, reportsMaster Plan, protocols, reportsProtocols, reportsManufacturing records, validation reportsMaster plan, protocols, reportsDocumentation required

V. Emerging Trends and Key Considerations in Cleaning Validation

The landscape of pharmaceutical cleaning validation is continuously evolving, driven by a growing understanding of contamination risks and advancements in analytical technologies.84 Several key trends and considerations are shaping current regulatory expectations worldwide.

A significant trend is the increasing global convergence towards risk-based cleaning validation programs.2 Regulatory agencies are moving away from prescriptive approaches and emphasizing the need for manufacturers to identify, assess, and control contamination risks specific to their products and processes. This approach allows for a more tailored and effective validation strategy, focusing resources on the areas of highest potential risk to product quality and patient safety.

Central to this risk-based approach is the role of Health-Based Exposure Limits (HBELs) in setting scientifically justified acceptance criteria for residues.2 HBELs, such as PDE and ADE values, are derived from toxicological data and represent the daily exposure level below which no adverse health effects are anticipated. Their adoption by major regulatory bodies signifies a move towards more scientifically defensible and patient-centric residue limits, replacing older, more arbitrary criteria.

Another prominent trend is the emphasis on a lifecycle approach to cleaning validation.4 This involves viewing cleaning validation not as a one-time event but as a continuous process that includes the initial design and development of the cleaning procedure, its qualification through validation studies, and the ongoing monitoring and verification of its effectiveness throughout the product lifecycle. This approach ensures that cleaning procedures remain effective despite changes in products, equipment, or processes.

The growing importance of data integrity and the potential for digital record-keeping systems are also emerging trends.6 Regulatory agencies increasingly expect manufacturers to have robust systems in place to ensure the accuracy, reliability, and traceability of all data related to cleaning validation. Digital systems offer advantages in terms of data management, real-time monitoring, and audit trails, making them increasingly preferred over traditional paper-based records.

Robust cleaning validation protocols are essential and must address worst-case scenarios.4 These protocols should consider factors such as the potency and solubility of the products being manufactured, the complexity of the equipment being cleaned, and the potential for residues to accumulate in hard-to-reach areas. Validating the cleaning process under the most challenging conditions provides greater assurance of its effectiveness under normal operating conditions.

While visual inspection remains a crucial minimum requirement to verify the absence of visible residues after cleaning, it is often considered insufficient on its own, particularly for highly potent compounds or when residue limits are very low.4 Therefore, validated sampling and analytical methods with appropriate sensitivity are necessary to detect non-visible residues and ensure compliance with established acceptance criteria.4 Common sampling methods include swabbing and rinsing, and analytical techniques such as HPLC and TOC are frequently employed.

Manufacturers must also consider the nuances between manual and automated cleaning processes when developing and validating their cleaning procedures.1 Manual cleaning can be more variable and may require more stringent controls and training, while automated Clean-in-Place (CIP) systems need to be properly validated to ensure consistent and effective cleaning cycles.

Finally, the role of cleaning verification in ensuring the ongoing effectiveness of validated cleaning procedures is gaining prominence.2 Cleaning verification involves performing periodic testing after routine cleaning to confirm that the cleaning procedure continues to meet the validated acceptance criteria, providing ongoing assurance of cleanliness.

VI. Conclusion

This report has provided a comprehensive overview of the latest pharmaceutical cleaning validation guidance from key global regulatory agencies. The analysis reveals a significant degree of convergence in the fundamental principles of cleaning validation across these authorities. There is a clear global trend towards the adoption of risk-based approaches, emphasizing the identification and control of contamination hazards specific to each manufacturing process and product. The central role of Health-Based Exposure Limits (HBELs) in establishing scientifically justified acceptance criteria for residues is also a consistent theme across the guidance from the US FDA, MHRA, EU GMP, Health Canada, PIC/S, WHO, and the aligning expectations in India’s revised Schedule M.

While the underlying principles are largely shared, there are nuances and specific emphases within the guidance of each regulatory body. For instance, the EU GMP, particularly Annex 15 and the revised Annex 1, provides a detailed framework with a strong focus on HBELs and stringent requirements for sterile product manufacturing. The MHRA aligns with EU GMP but emphasizes digital record-keeping and thorough validation of manual cleaning processes. Health Canada’s guidelines offer comprehensive details and align closely with PIC/S recommendations. PIC/S plays a crucial role in international harmonization, and its Annex 15 is widely adopted. Japan’s PMDA, while harmonizing with international standards and participating in PIC/S, also refers to ICH guidelines for specific aspects of cleaning validation. The WHO provides global recommendations, with TRS 1033 Annex 2 offering key considerations for implementing HBELs. India’s revised Schedule M marks a significant step towards aligning with global GMP standards, including a focus on validation and risk management.

Given the increasing complexity and scrutiny of cleaning validation processes, it is imperative for pharmaceutical manufacturers to remain informed about the latest regulatory requirements and interpretations issued by the authorities relevant to their markets. A robust, scientifically sound, and risk-based cleaning validation program, incorporating HBELs and a lifecycle approach, is essential for ensuring global regulatory compliance, preventing cross-contamination, and ultimately safeguarding patient safety and the quality of pharmaceutical products. The evolving landscape of pharmaceutical cleaning validation underscores the need for continuous improvement and adaptation to meet the ever-increasing expectations of regulatory agencies worldwide.

References

  1. Cleaning Validation: Protocol & Guidelines | SafetyCulture, accessed May 15, 2025, https://safetyculture.com/topics/cleaning-validation/
  2. Cleaning Validation Guidelines in Pharmaceutical Industry – Amplelogic, accessed May 15, 2025, https://amplelogic.com/cleaning-validation-guidelines-in-pharmaceutical-industry/
  3. Cleaning Validation: 8 Steps for FDA Compliance Success – Zamann Pharma Support, accessed May 15, 2025, https://zamann-pharma.com/2024/07/17/cleaning-validation-7-steps-for-fda-compliance-success/
  4. Cleaning validation guide (GUI-0028) – Canada.ca, accessed May 15, 2025, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/validation/cleaning-validation-guidelines-guide-0028/document.html
  5. Annex 3 – World Health Organization (WHO), accessed May 15, 2025, https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1019-annex3-gmp-validation.pdf
  6. Discover the latest cleaning validation guidelines in pharma for 2025. – Leucine, accessed May 15, 2025, https://www.leucine.io/cleaning-validation-blogs/cleaning-validation-guidelines
  7. Questions and Answers on Current Good Manufacturing Practice …, accessed May 15, 2025, https://www.fda.gov/drugs/guidances-drugs/questions-and-answers-current-good-manufacturing-practice-requirements-equipment
  8. Validation of Cleaning Processes (7/93) | FDA, accessed May 15, 2025, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/validation-cleaning-processes-793
  9. FDA takes a Look at Cleaning Validation – ECA Academy, accessed May 15, 2025, https://www.gmp-compliance.org/gmp-news/fda-takes-a-look-at-cleaning-validation
  10. ICH Q7 Chapter 5 & 12.7: – Process Equipment & Cleaning Validation – Parenteral Drug Association, accessed May 15, 2025, https://www.pda.org/docs/default-source/website-document-library/chapters/presentations/india/section-05-and-12-7—process-equipment-and-cleaning-validation.pdf?sfvrsn=a072b28e_1
  11. FDA Inspections and Cleaning – Parexel, accessed May 15, 2025, https://www.parexel.com/insights/blogs/fda-inspections-and-cleaning-4
  12. Avoiding Common FDA 483 Observations in Cleaning Validation – ValGenesis, accessed May 15, 2025, https://www.valgenesis.com/blog/avoiding-common-fda-483-observations-in-cleaning-validation
  13. British Authority MHRA provides Interpretation on Cleaning Validation – ECA Academy, accessed May 15, 2025, https://www.gmp-compliance.org/gmp-news/british-authority-mhra-provides-interpretation-on-cleaning-validation
  14. Cleaning Validation Guidelines 2025 | Global Regulatory Insights for Audit-Ready Pharma, accessed May 15, 2025, https://www.leucine.io/cleaning-validation/cleaning-validation-guidelines-2025
  15. Guidance for ‘specials’ manufacturers – GOV.UK, accessed May 15, 2025, https://www.gov.uk/government/publications/guidance-for-specials-manufacturers
  16. Cross Contamination Control in Shared Facilities and Equipment. Reflection on common deficiencies and expectations as seen in recent PIC/S guidance. – MHRA Inspectorate, accessed May 15, 2025, https://mhrainspectorate.blog.gov.uk/2020/08/18/cross-contamination-control-in-shared-facilities-and-equipment-reflection-on-common-deficiencies-and-expectations-as-seen-in-recent-pic-s-guidance/
  17. Cross-contamination control and Health Based Exposure Limits (HBEL) Q&As, accessed May 15, 2025, https://mhrainspectorate.blog.gov.uk/2018/10/22/cross-contamination-control-and-health-based-exposure-limits-hbel-qas/
  18. EudraLex – Volume 4 – European Commission, accessed May 15, 2025, https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  19. health.ec.europa.eu, accessed May 15, 2025, https://health.ec.europa.eu/document/download/7c6c5b3c-4902-46ea-b7ab-7608682fb68d_en?filename=2015-10_annex15.pdf
  20. EU GMP Annex 15: Qualification and Validation – ECA Academy, accessed May 15, 2025, https://www.gmp-compliance.org/guidelines/gmp-guideline/eu-gmp-annex-15-qualification-and-validation
  21. EU GMP Annex 1 (August 2022): impact on cleaning and disinfection, accessed May 15, 2025, https://manufacturingchemist.com/eu-gmp-annex-1-august-2022-impact-on-cleaning-and-disinfection-205414
  22. EU GMP Annex 1 – Impact on Cleaning and Disinfection – Contec Cleanroom, accessed May 15, 2025, https://cleanroom.contecinc.com/resource/eu-gmp-annex-1-impact-on-cleaning-and-disinfection
  23. Cleaning Validation – GMP Navigator, accessed May 15, 2025, https://www.gmp-navigator.com/files/eca/userFiles/seminarpdf/ECA-Cleaning-Validation-2024-Live-Online-Training-v6.pdf
  24. Cleaning Validation – gmp-compliance.org, accessed May 15, 2025, https://www.gmp-compliance.org/files/eca/userFiles/seminarpdf/ECA-Cleaning-Validation-2024-2025-LOT.pdf
  25. Guidance on good manufacturing practice and good distribution practice: Questions and answers | European Medicines Agency (EMA), accessed May 15, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers
  26. APIC: Update of the “Cleaning Validation” Guide for APIs – ECA Academy, accessed May 15, 2025, https://www.gmp-compliance.org/gmp-news/apic-update-of-the-cleaning-validation-guide-for-apis
  27. Guidance on aspects of cleaning validation in active pharmaceutical ingredient plants – APIC (CEFIC), accessed May 15, 2025, https://apic.cefic.org/wp-content/uploads/2021/09/APIC_Cleaning-validation-guide_2021.pdf
  28. Cleaning validation guide (GUI-0028) – Summary – Canada.ca, accessed May 15, 2025, https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/validation/cleaning-validation-guidelines-guide-0028.html
  29. Cleaning validation guide. : H139-6/2021E-PDF – Government of Canada Publications, accessed May 15, 2025, https://publications.gc.ca/site/eng/9.882942/publication.html
  30. Cleaning validation guide (GUI-0028), accessed May 15, 2025, https://assets.ctfassets.net/a44nqpvb9zjg/78mndAlqro9UU1jGjZFZ9f/590f73df600ae18473ae2d7f23805f85/Health_Canada_GUI-0028_EN.pdf
  31. www.canada.ca, accessed May 15, 2025, https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/validation/cleaning-validation-guidelines-guide-0028/document/pub1-eng.pdf
  32. Health Products and Food Branch Inspectorate Graham Spry Building, 3rd Floor 250 Lanark Avenue Address Locator # 2003D OTTAWA – ResearchGate, accessed May 15, 2025, https://www.researchgate.net/profile/Vit-Mateju/post/Dose_any-one_knows_about_cleaning_validation_for_pathogens_from_fermentor/attachment/5fdcd9b5e35e2b0001ff40f8/AS%3A970133140951042%401608309173686/download/gui_0028_tc-tm-eng.pdf
  33. guide to good manufacturing practice for medicinal products – PIC/S, accessed May 15, 2025, https://picscheme.org/users_uploads/news_news_documents/ps_inf_11_2015_pics_gmp_revised_annex_15.pdf
  34. Publications – PIC/S, accessed May 15, 2025, https://picscheme.org/en/publications
  35. PIC/S Validation-Master Plan, IQ, OQ, non-sterile Process Validation, Cleaning Validation (PI 006-3) Sept 2007 – ECA Academy, accessed May 15, 2025, https://www.gmp-compliance.org/guidelines/gmp-guideline/pic-s-validation-master-plan-iq-oq-non-sterile-process-validation-cleaning-validation-pi-006-3-sept-2007
  36. Resources – Cleaning Validation Simplified, accessed May 15, 2025, https://cleaningvalidation.com/resources/
  37. Guide to good manufacturing practice for medicinal products, part I – PIC/S, accessed May 15, 2025, https://picscheme.org/docview/6606
  38. PICS GMP Guide (Annexes) – Therapeutic Goods Administration (TGA), accessed May 15, 2025, https://www.tga.gov.au/sites/default/files/gmp-guide-annexes.pdf
  39. picscheme.org, accessed May 15, 2025, https://picscheme.org/docview/3447
  40. PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS, accessed May 15, 2025, https://picscheme.org/layout/document.php?id=156
  41. GMP Guide Part II APIs – PIC/S, accessed May 15, 2025, https://picscheme.org/docview/6607
  42. GUIDELINE ON SETTING HEALTH BASED EXPOSURE LIMITS FOR USE IN RISK IDENTIFICATION IN THE MANUFACTURE OF DIFFERENT MEDICINAL PROD – PIC/S, accessed May 15, 2025, https://picscheme.org/docview/2467
  43. FY 2023 GMP / GCTP Annual Report – PMDA, accessed May 15, 2025, https://www.pmda.go.jp/files/000273632.pdf
  44. Japan GMP Compliance: Ensuring Standards | PBM – Pacific Bridge Medical, accessed May 15, 2025, https://www.pacificbridgemedical.com/uncategorized/japan-gmp-standards-how-to-ensure-compliance/
  45. Japan Drug GMP Compliance Guide | Blog – PBM – Pacific Bridge Medical, accessed May 15, 2025, https://www.pacificbridgemedical.com/uncategorized/a-quick-guide-to-japans-drug-gmp-regulations/
  46. Regulations and Approval/Certification of Medical Devices – PMDA, accessed May 15, 2025, https://www.pmda.go.jp/english/review-services/reviews/0004.html
  47. Pharmaceuticals and Medical Devices Agency – PMDA, accessed May 15, 2025, https://www.pmda.go.jp/english/
  48. GMP system of Japan, accessed May 15, 2025, https://www.mhlw.go.jp/file/04-Houdouhappyou-11123000-Iyakushokuhinkyoku-Shinsakanrika/gmp.pdf
  49. Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices – Japanese Law Translation, accessed May 15, 2025, https://www.japaneselawtranslation.go.jp/en/laws/view/3213/en
  50. Current GMP Inspection of PMDA, accessed May 15, 2025, https://www.pmda.go.jp/files/000152330.pdf
  51. GMP Guideline for Drug Products – National Institute of Health Sciences, accessed May 15, 2025, https://www.nihs.go.jp/drug/section3/hiyama070518-2.pdf
  52. ich harmonised tripartite guideline good manufacturing practice guide for active pharmaceutical ingredients q7, accessed May 15, 2025, https://www.pmda.go.jp/files/000156709.pdf
  53. Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities – EMA, accessed May 15, 2025, https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-setting-health-based-exposure-limits-use-risk-identification-manufacture-different-medicinal-products-shared-facilities_en.pdf
  54. Production – Health products policy and standards, accessed May 15, 2025, https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/production
  55. Annex 2 – World Health Organization (WHO), accessed May 15, 2025, https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/inspections/trs1033-annex2-points-to-consider-when-incl-hbels-in-cleaning-validation.pdf?sfvrsn=5ee0cd8a_1&download=true
  56. TRS 1033 – Annex 2: Points to consider when including Health-Based Exposure Limits (HBELs) in cleaning validation, accessed May 15, 2025, https://www.who.int/publications/m/item/annex-2-trs-1033
  57. WHO Points to consider when including Health-Based Exposure Limits (HBELs) in cleaning validation – ECA Academy, accessed May 15, 2025, https://www.gmp-compliance.org/guidelines/gmp-guideline/who-points-to-consider-when-including-health-based-exposure-limits-hbels-in-cleaning-validation
  58. WHO TRS 1033 published in March 2021 – Pharmaguideline Forum, accessed May 15, 2025, https://ask.pharmaguideline.com/t/who-trs-1033-published-in-march-2021/7255
  59. Copy of FINAL MMS TRS 1033 – ANNEX 2: POINTS TO CONSIDER, accessed May 15, 2025, https://saunicphsupporthub.blob.core.windows.net/public-uploads/docs/67680c08-9ab6-4b79-a722-7cd42e909a41/1738778278-1.3.1-11e31079-3911-4c1e-8940-ebad010328d8/export.pdf
  60. cdn.who.int, accessed May 15, 2025, https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/inspections/trs1033-annex2-points-to-consider-when-incl-hbels-in-cleaning-validation.pdf
  61. 5 Key Changes in Revised Schedule M: A Comprehensive Guide – Pharmadocx Consultants, accessed May 15, 2025, https://pharmadocx.com/key-changes-in-revised-schedule-m/
  62. Schedule M Compliance: What to Do After the Deadline – Inotek, accessed May 15, 2025, https://inotek.co.in/blogs/schedule-m-compliance-deadline-recovery-guide?slug=schedule-m-compliance-deadline-recovery-guide
  63. Pharmaceutical SMEs in India Gain Time to Meet Enhanced GMP Standards Under Revised Schedule M, accessed May 15, 2025, https://www.india-briefing.com/news/india-extends-gmp-compliance-deadline-to-december-2025-35679.html/
  64. The Importance of Sanitation and Facility Maintenance for Schedule M Revised Compliance, accessed May 15, 2025, https://www.pharmagmp.in/the-importance-of-sanitation-and-facility-maintenance-for-schedule-m-revised-compliance/
  65. Revised Schedule M Overviewo | PDF | Pharmacovigilance | Verification And Validation, accessed May 15, 2025, https://www.scribd.com/document/852280659/Revised-Schedule-M-Overviewo
  66. cdsco.gov.in, accessed May 15, 2025, https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCircularFile/Guidance%20document%20for%20risk%20based%20inspection.pdf
  67. schedule-m-1.pdf – Indian Pharmaceutical Association, accessed May 15, 2025, https://ipapharma.org/wp-content/uploads/2019/02/schedule-m-1.pdf
  68. Cleaning Methodology and Validation – Indian Pharmaceutical Alliance, accessed May 15, 2025, https://www.ipa-india.org/wp-content/uploads/2023/03/ipa-cleaning-methodology-and-valodation.pdf
  69. New Schedule M – sidvim, accessed May 15, 2025, https://sidvim.com/pdf/insights/New-SCHEDULE-M.pdf
  70. MINISTRY OF HEALTH AND FAMILY WELFARE (Department of Health and Family Welfare) NOTIFICATION New Delhi, the 28th December, 2023 – Pharmadocx Consultants, accessed May 15, 2025, https://pharmadocx.com/wp-content/uploads/2024/01/Notified-Schedule-M-dt-28.12.2023-1.pdf
  71. SCHEDULE M-III – CDSCO, accessed May 15, 2025, https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadImmunization/Final_Schedulemii.pdf
  72. No. G-30015/25/2021-Scheme Government of India Ministry of Chemicals & Fertilizers Department of Pharmaceuticals ***** Shast, accessed May 15, 2025, https://pharma-dept.gov.in/sites/default/files/Revised%20guidelines%20SPI%20dated%2014.03.2024.pdf
  73. Schedule M – Pharmaceutical Guidelines, accessed May 15, 2025, https://www.pharmaguideline.com/2010/10/schedule-m.html
  74. SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS GAZETTE OF – Rajasthan Pharmacy Council, accessed May 15, 2025, https://www.rajasthanpharmacycouncil.in/admin/attachments/Revised%20Schedule%20%20M%204.pdf
  75. A REVIEW ARTICLE ON AN EXISTING SCHEDULE M VS REVISED SCHEDULE M, accessed May 15, 2025, https://ijpsr.com/bft-article/a-review-article-on-an-existing-schedule-m-vs-revised-schedule-m/?view=fulltext
  76. Key Notes on Revised Schedule M: Biological products – The Health Master, accessed May 15, 2025, https://thehealthmaster.com/2025/01/15/revised-schedule-m-biological-products/
  77. Revised Schedule M: A Complete Guide to Pharma Compliance – PharmaState Academy, accessed May 15, 2025, https://pharmastate.academy/revised-schedule-m-complete-guide-to-pharma-compliance/
  78. a review article on an existing schedule m vs revised schedule m – ResearchGate, accessed May 15, 2025, https://www.researchgate.net/publication/389465557_A_REVIEW_ARTICLE_ON_AN_EXISTING_SCHEDULE_M_VS_REVISED_SCHEDULE_M
  79. Conditional extension of timeline to small and medium pharmaceutical manufacturers for compliance with revised Schedule ‘M’ notification – PIB, accessed May 15, 2025, https://pib.gov.in/PressReleasePage.aspx?PRID=2102291
  80. Drugs (Amendment) Rules 2023 – Schedule M of Drugs Rules, 1945 – CliniExperts, accessed May 15, 2025, https://cliniexperts.com/regulatory-update/drugs-amendment-rules-2023-schedule-m-of-drugs-rules-1945/
  81. Implementing Revised Schedule M Guideline | MSME’s Support – Pharma Focus Asia, accessed May 15, 2025, https://www.pharmafocusasia.com/articles/schedule-m-guideline-revision-and-its-nationwide-implementation
  82. Timeline for Revised Schedule M Implementation Extended to December 2025 – Qvents, accessed May 15, 2025, https://qvents.in/news/timeline-revised-schedule-m-implementation-extended-to-december-2025/
  83. Update on Drugs & Cosmetics Act and Revised Schedule M: 28 June 2024. – Indian Pharmaceutical Alliance, accessed May 15, 2025, https://www.ipa-india.org/wp-content/uploads/2024/06/Regulatory-Reforms-in-India-Ranga-Chandresekhar-Joint-Drugs-Controller-India-CDSCO-GoI.pdf
  84. Modern Cleaning Validation: Ensuring Safety and Quality in Today’s OSD Production, accessed May 15, 2025, https://www.tabletscapsules.com/3641-Technical-Articles/618245-Modern-Cleaning-Validation/
  85. Im looking for guideline of cleaning validation procedure for cosmetics finished products (topical )? | ResearchGate, accessed May 15, 2025, https://www.researchgate.net/post/Im_looking_for_guideline_of_cleaning_validation_procedure_for_cosmetics_finished_products_topical
  86. Cleaning Validation | Pharmallies, accessed May 15, 2025, https://pharmallies.com/wp-content/uploads/2024/06/Cleaning_Validation_White_Paper_PharmAllies_Final_06.03.2024.pdf
  87. Questions and Answers about Cleaning Validation – Part 1 – GMP Journal, accessed May 15, 2025, https://www.gmp-journal.com/current-articles/details/questions-and-answers-about-cleaning-validation-part-1.html
  88. Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients – FDA, accessed May 15, 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients
  89. More on Health Canada’s Guideline – Cleaning Validation Simplified, accessed May 15, 2025, https://cleaningvalidation.com/memos/more-on-health-canadas-guideline/
Scroll to Top